800-TCR

N/A

Report date: 2026/01/06 15:03:40

Base Information

Drug Name800-TCR
Drug Alias NameHERV-E targeting TCR-T cell800-TCRTCR-800
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionHuman Endogenous retrovirus group E inhibitors
TargetsHuman Endogenous retrovirus group E
Therapy Area/IndicationsKidney Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesT-Cure Bioscience Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Heart, Lung, And Blood Institute (Nhlbi)
Inactive CompaniesN/A
Active IndicationsKidney Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A